EUVIMEDEUVIMED entdecken
Open Access

Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach

Victória E Helfer, Daniel Gonzalez, Kathryn E Kyler iD, Tyler C Dunlap, Veronica Williams, Jansynn Radford, Rangaraj Selvarangan, Anjana Sasidharan, Sherwin Chan, Nathan Artz, Brandon Retke, Paul Toren und 2 weitere

Clinical Pharmacokinetics · 2025

DOI: 10.1007/s40262-025-01517-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Victória E Helfer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Lansoprazole, Models, Biological, Obesity, Proton Pump Inhibitors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIDDK NIH HHS, National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Pediatric pharmacokinetics pose unique challenges, particularly concerning drug dosing in the presence of obesity and genetic variability in drug-metabolizing enzymes such as cytochrome P450 (CYP) 2C19. This study aimed to develop a lansoprazole pediatric population pharmacokinetic (popPK) model considering obesity, obesity-associated changes in inflammatory cytokines and the liver, and CYP2C19 genotype, and to assess implications for dosing strategies. METHODS: Pediatric subjects with and without obesity (6-21 years, n = 47) received one oral dose of 1.2 mg/kg fat-free mass (FFM), not exceeding 60 mg. Plasma concentrations were measured at multiple time points, and a popPK analysis using NONMEM with stepwise covariate modeling was performed. Simulations compared exposures between children without and with obesity (BMI percentile ≥ 95th) after two dosing strategies: U.S. Food and Drug Administration (FDA)-approved total body weight-tiered and FFM-based dosing. RESULTS: A total of 537 lansoprazole concentrations were modeled using a two-compartment model with Weibull absorption and linear elimination. Parameters were allometrically scaled to FFM with fixed exponents of 0.75 for clearances and 1 for volumes. CYP2C19 was identified as a significant covariate for CL/F. No significant differences in lansoprazole exposure were observed between children with and without obesity, with both dosing approaches. Higher exposure was noted in poor/intermediate metabolizers of CYP2C19. FFM-based dosing led to similar levels of exposure between children (aged 6-11 years) and adolescents (aged 12-17 years). CONCLUSIONS: Obesity was not associated with differences in lansoprazole pharmacokinetics in children. A FFM-based dosing approach could result in comparable exposure between children and adolescents. Dose adjustments are supported for poor/intermediate metabolizers of CYP2C19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LansoprazoleModels, BiologicalObesityProton Pump InhibitorsPediatric ObesityCytochrome P450 Family 2HumansChildAdolescentFemaleMaleGenotypeCytochrome P-450 CYP2C19Young Adult

Substanzen

LansoprazoleCytochrome P-450 CYP2C19Proton Pump InhibitorsCYP2C19 protein, humanCytochrome P450 Family 2

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
  • Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Duke Clinical Research Institute, Durham, NC, USA.
  • Children's Mercy Kansas City, Kansas City, MO, USA. kekyler@cmh.edu.
  • University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. kekyler@cmh.edu.
  • Nemours Children's Health, Orlando, FL, USA.

ORCID-Profile: Kathryn E Kyler

Förderung

  • NICHD NIH HHS
  • NIDDK NIH HHS
  • National Institute of Child Health and Human Development
  • NIGMS NIH HHS
  • NCATS NIH HHS
  • NASPGHAN Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Helfer, V. E., Gonzalez, D., Kyler, K. E., Dunlap, T. C., Williams, V., Radford, J., Selvarangan, R., Sasidharan, A., Chan, S., Artz, N., Retke, B., Toren, P., Gibson, K., & Shakhnovich, V. (2025). Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01517-0

Vancouver

Helfer VE, Gonzalez D, Kyler KE, Dunlap TC, Williams V, Radford J, et al. Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01517-0

BibTeX
@article{Helfer2025,
  author = {Helfer, Victória E and Gonzalez, Daniel and Kyler, Kathryn E and Dunlap, Tyler C and Williams, Veronica and Radford, Jansynn and Selvarangan, Rangaraj and Sasidharan, Anjana and Chan, Sherwin and Artz, Nathan and Retke, Brandon and Toren, Paul and Gibson, Kim and Shakhnovich, Valentina},
  title = {Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s40262-025-01517-0}
}
Kostenlos starten →